There’s a new sense of excitement surrounding Lyell Immunopharma Inc. (LYEL)

Lyell Immunopharma Inc. (NASDAQ: LYEL) closed the day trading at $3.04 up 2.01% from the previous closing price of $2.98. In other words, the price has increased by $+0.0600 from its previous closing price. On the day, 801838 shares were traded. LYEL stock price reached its highest trading level at $3.1200 during the session, while it also had its lowest trading level at $2.8700.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…

Sponsored

Ratios:

For a better understanding of LYEL, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 12.90 and its Current Ratio is at 12.90. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Morgan Stanley on November 14, 2022, Downgraded its rating to Equal-Weight and sets its target price to $7 from $15 previously.

On November 11, 2022, Goldman Downgraded its rating to Neutral which previously was Buy and also lowered its target price recommendation from $13 to $7.

On October 17, 2022, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $12.H.C. Wainwright initiated its Buy rating on October 17, 2022, with a $12 target price.

Insider Transactions:

The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Sep 23 when Klausner Richard sold 11,100 shares for $6.40 per share. The transaction valued at 71,041 led to the insider holds 988,900 shares of the business.

Valuation Measures:

For the stock, the TTM Price-to-Sale (P/S) ratio is 18.99 while its Price-to-Book (P/B) ratio in mrq is 0.92.

Stock Price History:

Over the past 52 weeks, LYEL has reached a high of $8.74, while it has fallen to a 52-week low of $2.74. The 50-Day Moving Average of the stock is 3.6509, while the 200-Day Moving Average is calculated to be 5.4574.

Shares Statistics:

Over the past 3-months, LYEL traded about 1.17M shares per day on average, while over the past 10 days, LYEL traded about 1.18M shares per day. A total of 248.32M shares are outstanding, with a floating share count of 210.08M. Insiders hold about 3.10% of the company’s shares, while institutions hold 66.00% stake in the company. Shares short for LYEL as of Oct 13, 2022 were 19.2M with a Short Ratio of 19.82M, compared to 15.32M on Sep 14, 2022. Therefore, it implies a Short% of Shares Outstanding of 7.75% and a Short% of Float of 11.14%.

Earnings Estimates

Current recommendations for the stock of the company come from 3 analysts. On average, analysts expect EPS of -$0.31 for the current quarter, with a high estimate of -$0.23 and a low estimate of -$0.39, while EPS last year was -$0.2. The consensus estimate for the next quarter is -$0.38, with high estimates of -$0.23 and low estimates of -$0.54.

Analysts are recommending an EPS of between -$0.89 and -$1.35 for the fiscal current year, implying an average EPS of -$1.11. EPS for the following year is -$1.56, with 3 analysts recommending between -$0.94 and -$2.

Revenue Estimates

A total of 4 analysts have provided revenue estimates for LYEL’s current fiscal year. The highest revenue estimate was $43.29M, while the lowest revenue estimate was $10.65M, resulting in an average revenue estimate of $32.63M. In the same quarter a year ago, actual revenue was $10.65M, up 206.40% from the average estimate.